Free Online CME

≡ Menu

Biologic Therapies:
Precision Medicine in the Biologic Era
Online Monograph

Print this Content

Release Date:  July 26, 2017
Expiration Date:  July 26, 2019

Estimated Time of Completion:  1 hour

Description

The Biologic Therapies VII: Precision Medicine in the Biologic Era Online Monograph features international, multi-disciplinary faculty of experts critically appraising recent basic laboratory breakthroughs in terms of their potential clinical implications and providing in-depth analyses of approved agents, new agents, predicting toxicity, clinical controversies, and new indications.

Learning Objectives

  1. Describe recent advances in biologic drug development, regulations, and indications in immune-mediated inflammatory diseases (IMIDs).
  2. Critically appraise data on genetics and personalized medicine as applied to rheumatic diseases and IMIDs.
  3. Analyze recent investigations on efficacy and toxicity of biologic agents across IMIDs.
  4. Detail current knowledge related to predicting outcomes in patients with rheumatoid arthritis (RA).
  5. Summarize updates in diagnosis, classification, therapies, and immune-system targets in both psoriatic arthritis (PsA) and spondyloarthopathies (SpA) and describe their clinical implications.
  6. Critically assess clinical data on biologic use in immune-related diseases in the areas of pulmonary disease, dermatology, metabolic bone diseases, and systemic lupus erythematosus (SLE).
  7. Develop strategies to predict, prevent, and treat comorbid complications of biologic therapy including cardiovascular disease and serious infections.

Target Audience

The online series is designed for rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Directors and Faculty

Activity Directors

Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Theodore F. Classen DO Chair of Osteopathic Research and Education
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

M. Elaine Husni, MD, MPH
Director, Arthritis and Musculoskeletal Treatment Center
Vice Chair, Department of Rheumatic & Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Faculty

Adam J. Brown, MD
Fellow
Department of Rheumatologic and Immunologic Diseases
Cleveland Clinic
Cleveland, OH

Cassandra M. Calabrese, DO
Fellow
Department of Rheumatologic and Immunologic Diseases
Department of Infectious Diseases
Cleveland Clinic
Cleveland, OH

Alexander Hannan, DO
Fellow
Department of Rheumatologic and Immunologic Diseases
Cleveland Clinic
Cleveland, OH

Alana M. Nevares, MD
Fellow
Department of Rheumatologic and Immunologic Diseases
Cleveland Clinic
Cleveland, OH

Hiromichi Tamaki, MD
Fellow
Department of Rheumatologic and Immunologic Diseases
Cleveland Clinic
Cleveland, OH

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentations, could be perceived as a potential conflict of interest:

Leonard Calabrese, DO
  Abbvie, Inc.; Bristol Myers Squibb; Genentech/Roche; Janssen Scientific Affairs, LLC Consulting; Teaching and Speaking
  GlaxoSmithKline; Pfizer, Inc.; UCB Consulting
  Crescendo Teaching and Speaking
 
M. Elaine Husni, MD, MPH
  AbbVie Pharmaceuticals; Amgen; Genentec; Janssen Consulting
  Amgen; Bristol-Myers Squibb; Genzyme/Sanofi; Lilly; Regeneron Consulting; Membership on
advisory committee or review panels
  Novartis Pharmaceuticals Consulting;
Teaching and Speaking
  Pfizer, Inc. Membership on advisory committee or review panels

The following faculty have indicated they have no relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:

Adam J. Brown, MD
Cassandra M. Calabrese, DO
Alexander Hannan, DO
Alana M. Nevares, MD
Hiromichi Tamaki, MD

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:

AbbVie, Inc.
Amgen, Inc.
Bristol-Myers Squibb Co.
Celgene Corporation
Crescendo Bioscience, Inc.
Genentech
Janssen Scientific Affairs, LLC
Novartis Pharmaceuticals Corporation
UCB, Inc.

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education and
R.J. Fasenmyer Center for Clinical Immunology
.